Table 1.
Baseline characteristics.
|
DMT Groups |
|||||
|---|---|---|---|---|---|
| All pts | Bcell | S1P | Other | no DMT | |
| n | 67 | 20 | 12 | 29 | 6 |
| MS Type - n (%) | |||||
| RR | 55 (82.1%) | 19 (95%) | 4 (33.3%) | 28 (69.6%) | 4 (66.7) |
| SP | 10 (14.9%) | 0 | 8 (66.7%) | 1 (3.4%) | 1 (16.7) |
| PP | 2 (3%) | 1 (5%) | 0 | 0 | 1 (16.7) |
| Sex - n (%) female | 52 (77.6%) | 16 (80%) | 10 (83.3%) | 22 (75.9%) | 4 (66.7%) |
| Age - mean (SD) | 52.8 (10.7) | 46.3 (10.5) | 59.3 (8.8) | 52.7 (9.3) | 4 (66.7%) |
| Disease duration, y - mean (SD) | 16.6 (8.9) | 10 (9.9) | 16.7 (6.9) | 18.5 (5.5) | 20.2 (7.8) |
| AB level (raw) - mean, median (SD) IQR | 147.8, 250 (117.3) 2.4–250 | 44.8, 0.8 (89.9) 0.4–45.2 | 106.5, 49.3 (115.9) 3.2–250 | 221.7, 250 (74.0) 250–250 | 216.9, 250 (80.8) 200–250 |
| AB Level (log) - mean, median (SD) IQR | 3.6, 5.5 (2.6) 0.8–5.5 | 1.1, −0.2 (2.5) −0.9–3.8 | 3.1, 3.6 (2.4) 1.1–5.5 | 5.1, 5.5 (1.2) 5.5–5.5 | 5.3, 5.5 (0.6) 5.1–5.5 |
| AB positive (n,%) | 57 (85.1%) | 11 (55%) | 11 (91.7%) | 29 (100%) | 6 (100%) |
| Lymphocyte > 1.1 | 35 (53.8%) | 13 (65%) | 3 (25%) | 15 (51.7%) | 4 (66.7%) |
| IgG >=700 - n (%) | – | 19 (95%) | – | – | – |
| IgM >=40 - n (%) | – | 13 (65%) | – | – | – |
| IgA >=70 - n (%) | – | 16 (80%) | – | – | – |
| Time from last infusion to vaccine, months - mean, median (SD) IQR | – | 3.5, 3.0 (1.5) 2.75–5.0 | – | – | – |
| Vaccine - n (%) | |||||
| Pfizer | 47 (70.1%) | 13 (65%) | 8 (66.7%) | 26 (79.3%) | 3 (50%) |
| Moderna | 19 (28.4%) | 7 (35%) | 3 (25%) | 6 (20.7%) | 3 (50%) |
| J&J | 1 (1.5%) | 0 | 1 (8.3%) | 0 | 0 |